Cardiac Marker Testing Market to Reach US$ 10.5 Billion by 2031

According to a new research study by Global Insight Services (GIS), the cardiac marker testing market is expected to grow rapidly over the next 10 years to reach a value of more than the US $10.5 billion by 2031.

Cardiac markers are utilized in the treatment and risk stratification of patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers. These biomarkers can be helpful to detect a variety of heart disorders, comprising acute coronary syndrome, cardiac ischemia, and conditions involving obstructed blood flow to the heart. Physicians perform several cardiac marker tests over several hours to keep track of the blood sugar increase and determine the severity of a heart attack.

Request Sample Pages of this Research Report:

Global Cardiac Marker Testing Market: Key Drivers

The key factor boosting the growth of the market is the growing incidence of cardiovascular diseases. The prevalence of lifestyle diseases such as hypertension, obesity, dyslipidemia, and diabetes, which are major risk factors for CVD, is also on the rise. In 2016, more than 1.9 billion adults globally were overweight; of these, over 600 million people were obese. It is anticipated that ~41% of the world’s population will be overweight or obese by 2030. The association between obesity and the risk of coronary heart disease was published by investigators (Bogers RP, Bemelmans WJ, Hogeveen RT, et al.) by a meta-analysis of 21 long-term studies conducted by them with more than 300,000 participants. It was witnessed that participants who were overweight had a 32% higher risk of developing coronary artery disease (CAD), and those who were obese had an 81% higher risk as compared with participants who were a normal weight.

Report Findings

The reagents and kits segment is likely to dominate the market during the forecast period

The growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits combined with growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the primary factors boosting the market growth during the forecast period.

Troponin I and T is anticipated to be the fastest-growing segment in the cardiac marker testing market

The large share of this segment can be attributed to high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

The myocardial infarction segment is likely to dominate the market during the forecast period

The key factors such as the growing incidence of cardiovascular diseases coupled with the rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases across the globe are boosting the growth of the market.

The laboratory testing segment is likely to dominate the market during the forecast period

The key factors such as growing funding from public and private organizations for research on cardiac biomarkers coupled with ongoing clinical trials for the identification of novel cardiac biomarkers are boosting the growth of the market.

Market Restraints and Challenges

The major factor hindering the market growth is technical problems related to sample collection and storage. Many epidemiology studies use cardiac biomarkers to investigate different stages of diseases in humans. It requires careful handling and storage of precious biological samples with the goal of obtaining a large amount of information from limited samples and reducing future research costs with the use of banked samples. Sample collection is thus one of the key issues faced by service providers, followed by access to these samples. Similarly, stringent quality control is also required for these samples, and they need to be stored under the right conditions to avoid any damage. Adding to that, different samples are required for risk detection, screening, diagnosis, and monitoring processes. The validity of results from cardiac biomarker studies using archived specimens is dependent on the integrity of specimens and the manner in which they were collected, processed, and stored.

Competitive Landscape

The key players in the global cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), Tosoh Corporation (Japan).